Use of p38 inhibitors to reduce expression of DUX4
US11479770B2 · kind B2 · utility
0Cited by
46References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2018 |
| Grant date | Oct 25, 2022 |
| Priority date | — |
| Expiry date | Dec 29, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.